Castle Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSTL research report →
About the company
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma.
- CEO
- Derek J. Maetzold
- IPO
- 2019
- Employees
- 784
- HQ
- Friendswood, TX, US
Price Chart
- Market Cap
- $731.26M
- P/E
- -56.14
- P/S
- 2.15
- P/B
- 1.56
- EV/EBITDA
- -970.43
- Div Yield
- 0.00%
- Gross Margin
- 77.07%
- Op Margin
- -9.79%
- Net Margin
- -3.78%
- ROE
- -2.77%
- ROIC
- -4.82%
- Revenue
- $344.23M · 3.66%
- Net Income
- $-24,158,000 · -232.41%
- EPS
- $-0.83 · -225.76%
- Op Income
- $-42,810,000
- FCF YoY
- -22.48%
- 52W High
- $44.28
- 52W Low
- $14.59
- 50D MA
- $21.73
- 200D MA
- $28.72
- Beta
- 1.02
- Avg Volume
- 397.77K
Get TickerSpark's AI analysis on CSTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Oelschlager Kristen M | sell | 8,587 |
| Jun 15, 26 | MAETZOLD DEREK J | other | 550 |
| Jun 15, 26 | MAETZOLD DEREK J | sell | 1,357 |
| Jun 15, 26 | MAETZOLD DEREK J | sell | 1,153 |
| Jun 15, 26 | MAETZOLD DEREK J | other | 550 |
| Jun 15, 26 | MAETZOLD DEREK J | sell | 550 |
| Jun 15, 26 | MAETZOLD DEREK J | sell | 278 |
| May 28, 26 | Olson Tiffany | other | 11,766 |
| May 28, 26 | Goldberg Ellen | other | 11,766 |
| May 28, 26 | Harrison Miles | other | 11,766 |
Our CSTL coverage
Recent articles, reports, and earnings notes.
No research on CSTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSTL report →Similar companies
Peers in the same neighborhood.